2-(1-azepanyl)-N-[4-(dimethylsulfamoyl)phenyl]acetamide is a **chemical compound** that belongs to a class of **molecules called sulfonamides**. It has a complex structure with various functional groups, including:
* **Azepanyl ring**: A seven-membered nitrogen-containing ring.
* **Sulfonamide group**: A sulfur-containing group with two methyl (CH3) groups attached to the nitrogen.
* **Acetamide group**: A carbonyl group (C=O) linked to an amide group (NH2).
**Why is it important for research?**
This compound is **not widely known or studied** in current research, and there is no readily available information on its specific applications. However, its structure suggests it might be:
* **A potential drug candidate:** Sulfonamides are a well-established class of drugs with diverse pharmacological properties. The specific structure of this compound could give it potential for activity against certain biological targets.
* **A starting point for synthesis:** Its unique structure might be useful as a building block for synthesizing other, more complex molecules with specific properties.
* **A research tool:** Its chemical properties might be useful for studying certain biological processes or reactions.
**To determine the specific importance of 2-(1-azepanyl)-N-[4-(dimethylsulfamoyl)phenyl]acetamide, more information is needed.** Researchers could investigate its biological activity, synthesis potential, and chemical properties through:
* **Biological assays:** Testing the compound's effects on various cell lines or biological systems.
* **Synthesis reactions:** Studying its reactivity and ability to participate in chemical transformations.
* **Computational modeling:** Using computer simulations to predict its potential properties and interactions.
It's important to note that without further investigation, its importance for research remains speculative.
ID Source | ID |
---|---|
PubMed CID | 2480370 |
CHEMBL ID | 1550836 |
CHEBI ID | 117211 |
Synonym |
---|
MLS001172000 |
smr000590907 |
CHEBI:117211 |
2-(azepan-1-yl)-n-[4-(dimethylsulfamoyl)phenyl]acetamide |
AKOS002221024 |
HMS2911L15 |
STL229040 |
F3267-0036 |
2-(azepan-1-yl)-n-(4-(n,n-dimethylsulfamoyl)phenyl)acetamide |
783316-17-6 |
CHEMBL1550836 |
Q27203845 |
2-(1-azepanyl)-n-[4-(dimethylsulfamoyl)phenyl]acetamide |
VU0608209-1 |
Z46159698 |
DTXSID001324877 |
Class | Description |
---|---|
amino acid amide | An amide of an amino acid formed formally by conversion of the carboxy group to a carboxamido group. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
USP1 protein, partial | Homo sapiens (human) | Potency | 17.7828 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 1.6360 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 17.7828 | 0.0401 | 7.4590 | 31.6228 | AID1631; AID1634 |
snurportin-1 | Homo sapiens (human) | Potency | 1.6360 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 1.6360 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
geminin | Homo sapiens (human) | Potency | 6.5131 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |